Have a personal or library account? Click to login
Reactogenicity and safety of AS03B-adjuvanted H5N1 influenza vaccine in children: an open-label, one-way, crossover trial Cover

Reactogenicity and safety of AS03B-adjuvanted H5N1 influenza vaccine in children: an open-label, one-way, crossover trial

Asian Biomedicine
Volume 11 (2017): Issue 4 (August 2017)
By: Patricia Izurieta,  Pope Kosalaraksa,  Louise Frenette,  Mamadou Dramé,  Bruce L. Innis,  David W Vaughn and  Anne Schuind  
Open Access
|Mar 2018

Authors

Patricia Izurieta

patricia.s.izurieta@gsk.com

GSK, Wavre, Belgium

Pope Kosalaraksa

Department of Pediatrics, Khon Kaen University, Khon Kaen, Thailand

Louise Frenette

Q&T Research, Sherbrooke, Canada

Mamadou Dramé

GSK, King of Prussia, USA

Bruce L. Innis

Vaccines Discovery and Development, GSK, King of Prussia, USA

David W Vaughn

Vaccines Discovery and Development, GSK, King of Prussia, USA

Anne Schuind

Vaccines Discovery and Development, GSK, King of Prussia, USA
DOI: https://doi.org/10.1515/abm-2018-0008 | Journal eISSN: 1875-855X | Journal ISSN: 1905-7415
Journal RSS Feed
Language: English
Page range: 359 - 364
Published on: Mar 21, 2018
Published by: Chulalongkorn University
In partnership with: Paradigm Publishing Services
Publication frequency: 6 issues per year
Keywords:
AS03B adjuvanted,
children,
H5N1,
influenza,
pandemic,
safety,
vaccine
Related subjects:
Medicine,
Assistive professions, nursing,
Basic medical science,
Basic medical science, other,
Clinical medicine,
Clinical medicine, other

© 2018 Patricia Izurieta, Pope Kosalaraksa, Louise Frenette, Mamadou Dramé, Bruce L. Innis, David W Vaughn, Anne Schuind, published by Chulalongkorn University
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Previous articleVolume 11 (2017): Issue 4 (August 2017)Next article